Abstract
The cancer-associated alternative splicing (AS) events generate cancer-related transcripts which are involved in uncontrolled cell proliferation and drug resistance. However, the key AS variants implicated in tamoxifen (TAM) resistance in breast cancer remain elusive. In the current study, we investigated the landscape of AS events in nine pairs of primary and relapse breast tumors from patients receiving TAM-based therapy. We unrevealed a notable association between the inclusion of exon 7.2 in the 5’untranslated region (5’UTR) of ALDOA mRNA and TAM resistance. Mechanistically, the inclusion of ALDOA exon 7.2 enhances the translation efficiency of the transcript, resulting in increased ALDOA protein expression, mTOR pathway activity, and the promotion of TAM resistance in breast cancer cells. Moreover, the inclusion of exon 7.2 in ALDOA mRNA is mediated by MSI1 via direct interaction. In addition, elevated inclusion of ALDOA exon 7.2 or expression of MSI1 is associated with an unfavorable prognosis in patients undergoing endocrine therapy. Notably, treatment with Aldometanib, an ALDOA inhibitor, effectively restrains the growth of TAM-resistant breast cancer cells in vitro and in vivo. The present study unveils the pivotal role of an AS event in ALDOA, under the regulation of MSI1, in driving TAM resistance in breast cancer. Therefore, this study provides a promising therapeutic avenue targeting ALDOA to combat TAM resistance.
![](http://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41388-024-03134-w/MediaObjects/41388_2024_3134_Figa_HTML.png)
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41388-024-03134-w/MediaObjects/41388_2024_3134_Fig1_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41388-024-03134-w/MediaObjects/41388_2024_3134_Fig2_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41388-024-03134-w/MediaObjects/41388_2024_3134_Fig3_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41388-024-03134-w/MediaObjects/41388_2024_3134_Fig4_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41388-024-03134-w/MediaObjects/41388_2024_3134_Fig5_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41388-024-03134-w/MediaObjects/41388_2024_3134_Fig6_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41388-024-03134-w/MediaObjects/41388_2024_3134_Fig7_HTML.png)
Similar content being viewed by others
Data availability
The data and codes that support the findings of this study can be obtained from the corresponding authors upon reasonable request.
References
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33.
Herzog SK, Fuqua SAW. ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges. Br J Cancer. 2022;126:174–86.
Early Breast Cancer Trialists’ Collaborative G. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386:1341–52.
Early Breast Cancer Trialists’ Collaborative G, Davies C, Godwin J, Gray R, Clarke M, Cutter D, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771–84.
Yu S, Wang Y, Gong X, Fan Z, Wang Z, Liang Z, et al. LncRNA AGPG confers endocrine resistance in breast cancer by promoting E2F1 activity. Cancer Res. 2023;83:3220–36.
Ule J, Blencowe BJ. Alternative splicing regulatory networks: functions, mechanisms, and evolution. Mol Cell. 2019;76:329–45.
Bonnal SC, Lopez-Oreja I, Valcarcel J. Roles and mechanisms of alternative splicing in cancer—implications for care. Nat Rev Clin Oncol. 2020;17:457–74.
Chan JJ, Zhang B, Chew XH, Salhi A, Kwok ZH, Lim CY, et al. Pan-cancer pervasive upregulation of 3’ UTR splicing drives tumourigenesis. Nat Cell Biol. 2022;24:928–39.
Weber R, Ghoshdastider U, Spies D, Dure C, Valdivia-Francia F, Forny M, et al. Monitoring the 5’UTR landscape reveals isoform switches to drive translational efficiencies in cancer. Oncogene. 2022;42:638–50.
Al Kawas H, Saaid I, Jank P, Westhoff CC, Denkert C, Pross T, et al. How VEGF-A and its splice variants affect breast cancer development—clinical implications. Cell Oncol. 2022;45:227–39.
Gokmen-Polar Y, Neelamraju Y, Goswami CP, Gu Y, Gu X, Nallamothu G, et al. Splicing factor ESRP1 controls ER-positive breast cancer by altering metabolic pathways. EMBO Rep. 2019;20:e46078.
Xu Y, Huangyang P, Wang Y, Xue L, Devericks E, Nguyen HG, et al. ERalpha is an RNA-binding protein sustaining tumor cell survival and drug resistance. Cell. 2021;184:5215–29.e5217
Ohe K, Miyajima S, Abe I, Tanaka T, Hamaguchi Y, Harada Y, et al. HMGA1a induces alternative splicing of estrogen receptor alpha in MCF-7 human breast cancer cells. J Steroid Biochem Mol Biol. 2018;182:21–26.
Zhang H, Brown RL, Wei Y, Zhao P, Liu S, Liu X, et al. CD44 splice isoform switching determines breast cancer stem cell state. Genes Dev. 2019;33:166–79.
Ye LP, Lin CY, Wang X, Li QJ, Li Y, Wang M, et al. Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer. EMBO Mol Med. 2019;11:e10638.
Hinohara K, Wu HJ, Vigneau S, McDonald TO, Igarashi KJ, Yamamoto KN, et al. KDM5 histone demethylase activity links cellular transcriptomic heterogeneity to therapeutic resistance. Cancer Cell. 2018;34:939.
Zhou C, Zhong Q, Rhodes LV, Townley I, Bratton MR, Zhang Q, et al. Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration. Breast Cancer Res. 2012;14:R45.
Hinnebusch AG, Ivanov IP, Sonenberg N. Translational control by 5’-untranslated regions of eukaryotic mRNAs. Science. 2016;352:1413–6.
Lee S, Liu B, Lee S, Huang SX, Shen B, Qian SB. Global mapping of translation initiation sites in mammalian cells at single-nucleotide resolution. Proc Natl Acad Sci USA. 2012;109:E2424–2432.
Meng Z, King PH, Nabors LB, Jackson NL, Chen CY, Emanuel PD, et al. The ELAV RNA-stability factor HuR binds the 5’-untranslated region of the human IGF-IR transcript and differentially represses cap-dependent and IRES-mediated translation. Nucleic Acids Res. 2005;33:2962–79.
Hao P, Yu J, Ward R, Liu Y, Hao Q, An S, et al. Eukaryotic translation initiation factors as promising targets in cancer therapy. Cell Commun Signal. 2020;18:175.
Durie D, Lewis SM, Liwak U, Kisilewicz M, Gorospe M, Holcik M. RNA-binding protein HuR mediates cytoprotection through stimulation of XIAP translation. Oncogene. 2011;30:1460–9.
Geter PA, Ernlund AW, Bakogianni S, Alard A, Arju R, Giashuddin S, et al. Hyperactive mTOR and MNK1 phosphorylation of eIF4E confer tamoxifen resistance and estrogen independence through selective mRNA translation reprogramming. Gene Dev. 2017;31:2235–49.
Caldon CE, Sergio CM, Kang J, Muthukaruppan A, Boersma MN, Stone A, et al. Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells. Mol Cancer Ther. 2012;11:1488–99.
Hultsch S, Kankainen M, Paavolainen L, Kovanen RM, Ikonen E, Kangaspeska S, et al. Association of tamoxifen resistance and lipid reprogramming in breast cancer. BMC Cancer. 2018;18:850.
Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379:1926–36.
Bardia A, Hurvitz SA, DeMichele A, Clark AS, Zelnak A, Yardley DA, et al. Phase I/II trial of exemestane, ribociclib, and everolimus in women with HR(+)/HER2(−) advanced breast cancer after progression on CDK4/6 inhibitors (TRINITI-1). Clin Cancer Res. 2021;27:4177–85.
Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010;28:511–U174.
Yu SY, Gong X, Ma ZF, Zhang M, Huang L, Zhang J, et al. Endocrine resistant breast cancer cells with loss of ERα expression retain proliferative ability by reducing caspase7-mediated HDAC3 cleavage. Cell Oncol. 2020;43:65–80.
Weber R, Ghoshdastider U, Spies D, Dure C, Valdivia-Francia F, Forny M, et al. Monitoring the 5’UTR landscape reveals isoform switches to drive translational efficiencies in cancer. Oncogene. 2023;42:638–50.
Veiga DFT, Nesta A, Zhao Y, Deslattes Mays A, Huynh R, Rossi R, et al. A comprehensive long-read isoform analysis platform and sequencing resource for breast cancer. Sci Adv. 2022;8:eabg6711.
Leppek K, Das R, Barna M. Functional 5’ UTR mRNA structures in eukaryotic translation regulation and how to find them. Nat Rev Mol Cell Biol. 2018;19:158–74.
Tahmasebi S, Khoutorsky A, Mathews MB, Sonenberg N. Translation deregulation in human disease. Nat Rev Mol Cell Biol. 2018;19:791–807.
Osma-Garcia IC, Capitan-Sobrino D, Mouysset M, Bell SE, Lebeurrier M, Turner M, et al. The RNA-binding protein HuR is required for maintenance of the germinal centre response. Nat Commun. 2021;12:6556.
Wang X, Lin DH, Yan Y, Wang AH, Liao J, Meng Q, et al. The PIWI-specific insertion module helps load longer piRNAs for translational activation essential for male fertility. Sci China Life Sci. 2023;66:1459–81.
Niu Y, Lin Z, Wan A, Sun L, Yan S, Liang H, et al. Loss-of-function genetic screening identifies aldolase A as an essential driver for liver cancer cell growth under hypoxia. Hepatology. 2021;74:1461–79.
Grandjean G, de Jong PR, James B, Koh MY, Lemos R, Kingston J, et al. Definition of a novel feed-forward mechanism for glycolysis-HIF1alpha signaling in hypoxic tumors highlights aldolase A as a therapeutic target. Cancer Res. 2016;76:4259–69.
Li M, Zhang CS, Feng JW, Wei X, Zhang C, Xie C, et al. Aldolase is a sensor for both low and high glucose, linking to AMPK and mTORC1. Cell Res. 2021;31:478–81.
Chang YC, Yang YC, Tien CP, Yang CJ, Hsiao M. Roles of aldolase family genes in human cancers and diseases. Trends Endocrinol Metab. 2018;29:549–59.
Song Y, Guerrero-Juarez CF, Chen Z, Tang Y, Ma X, Lv C, et al. The Msi1-mTOR pathway drives the pathogenesis of mammary and extramammary Paget’s disease. Cell Res. 2020;30:854–72.
Zhang Y, Yao X, Zhou H, Wu X, Tian J, Zeng J, et al. OncoSplicing: an updated database for clinically relevant alternative splicing in 33 human cancers. Nucleic Acids Res. 2022;50:D1340–D1347.
Urbanski L, Brugiolo M, Park S, Angarola BL, Leclair NK, Yurieva M, et al. MYC regulates a pan-cancer network of co-expressed oncogenic splicing factors. Cell Rep. 2022;41:111704.
Wang J, Gribskov M. IRESpy: an XGBoost model for prediction of internal ribosome entry sites. BMC Bioinform. 2019;20:409.
Liu Q, Peng X, Shen MY, Qian Q, Xing JL, Li C, et al. Ribo-uORF: a comprehensive data resource of upstream open reading frames (uORFs) based on ribosome profiling. Nucleic Acids Res. 2023;51:D248–D261.
Hofacker IL. Vienna RNA secondary structure server. Nucleic Acids Res. 2003;31:3429–31.
Uren PJ, Vo DT, de Araujo PR, Potschke R, Burns SC, Bahrami-Samani E, et al. RNA-binding protein Musashi1 is a central regulator of adhesion pathways in glioblastoma. Mol Cell Biol. 2015;35:2965–78.
Acknowledgements
We thank patients for their contribution to the current study. We thank Liping Ye for providing transcriptome data of breast tumors.
Funding
The authors gratefully acknowledge the National Natural Science Foundation of China (82371877 to HS; 32270513 to WD). This study was funded in part by the Dalian Science and Technology Innovation Fund (2021RJ04, WD), the Startup Foundation for Advanced Talents and Science and Technology Innovation Foundation at Yangzhou University (137011856, HS), the Distinguished Doctoral Program of Green Yang Golden Phoenix of Yangzhou City (137012751, SY), the Talent Introduction Fund of Yangzhou University (137012455, SY), the Postgraduate Research & Practice Innovation Program of Jiangsu Province (SJCX22_1831 to NW; SJCX23_2043 to XL), the Undergraduate Innovation and Entrepreneurship Program of Nation (X20220739, XCX20230814, YX), the Natural Science Foundation of the Jiangsu Higher Education Institutions of China (23KJD310006, SY), and the Jiangsu Provincial Natural Science Foundation (SBK2024040451, SY).
Author information
Authors and Affiliations
Contributions
HS and SY conceived and coordinated the project. SY, YY, RW, WD, ZF, YS, ZW, NW, CB, XL, and ZL performed experiments and analyzed data. YW, SD, WD, RS, CY, and YY collected clinical samples and performed relevant experiments. SY, YX, and YC acquired bioinformatic data and performed bioinformatic analysis. SY wrote the manuscript which was discussed and edited by all authors.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics approval
The human subjects, human materials, human data, and the protocol of animal experiments in this study follow the guidelines of the Declaration of Helsinki. The study was approved by and performed under the supervision of the Ethic Committee of Yangzhou University (approval number: YXYLL-2021-08). All patients provided written informed consent.
Consent for publication
All authors agree with the content of the manuscript.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Yu, S., Wu, R., Si, Y. et al. Alternative splicing of ALDOA confers tamoxifen resistance in breast cancer. Oncogene (2024). https://doi.org/10.1038/s41388-024-03134-w
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41388-024-03134-w